DIPG-23. PHASE I STUDY OF ADOPTIVE CELLULAR THERAPY (X-ALT) PLUS TOTAL TUMOR RNA-DENDRITIC CELL VACCINE (TTRNA-DC) + HEMATOPOIETIC STEM CELLS (HSC) DURING RECOVERY FROM IRRADIATION(RT) WITH (GROUP A) OR WITHOUT (GROUP B) DOSE-INTENSIFIED TEMOZOLOMIDE (DI-TMZ) IN PATIENT (PTS) WITH NEWLY DIAGNOSED DIFFUSE BRAIN STEM GLIOMAS (DIPG) (BRAVO TRIAL)

Children with DIPG have a dismal prognosis and novel therapies are needed to improve survival. Based on lab studies demonstrating efficacy of x-ALT + ttRNA-DC vaccine +HSC following DI chemotherapy in DIPG models, we plan to conduct a study of this strategy in newly diagnosed pts with DIPG evaluatin...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Neuro Oncol
Główni autorzy: Gururangan, Sridharan, Sayour, Elias, Flores, Catherine, Hodik, Marcia, Mitchell, Duane
Format: Artigo
Język:Inglês
Wydane: Oxford University Press 2017
Hasła przedmiotowe:
Abstracts
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475097/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.038
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy